These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Criteria for judging proposals for national health care reform with respect to therapeutics. Nierenberg DW; Reidenberg MM Clin Pharmacol Ther; 1994 Jan; 55(1):1-4. PubMed ID: 8299310 [No Abstract] [Full Text] [Related]
4. Thrombolytic therapy for acute myocardial infarction in the 1990s. Effron MB; Morales RE Md Med J; 1991 Jun; 40(6):485-91. PubMed ID: 1830634 [TBL] [Abstract][Full Text] [Related]
5. Implications of the specialty drug marketplace for health-system pharmacy: a roundtable discussion. Armitstead J; Loyd L; Pane F; Rough S; Shane R Am J Health Syst Pharm; 2007 Nov; 64(22):2364-72. PubMed ID: 17989447 [No Abstract] [Full Text] [Related]
7. Developing new drugs for cancer. Mead GM; Williams CJ BMJ; 1991 Oct; 303(6809):1005-6. PubMed ID: 1805823 [No Abstract] [Full Text] [Related]
8. Health economics. Perfect combination. Youle M; Weston R; Trueman P; Swaden L; Leake H Health Serv J; 1999 Oct; 109(5675):26-7. PubMed ID: 10662318 [TBL] [Abstract][Full Text] [Related]
9. Maximizing the benefits of thrombolytic therapy for acute myocardial infarction. Cairns J; Armstrong PW; Belenkie I; Hirsh J; Johnstone DE; Knudtson M; Lemieux M; Massel D; Naylor CD; Roy L CMAJ; 1995 Mar; 152(6):819-22. PubMed ID: 7697574 [TBL] [Abstract][Full Text] [Related]
10. The extinction of drugs for clinical research: Can the ECNP medicines chest save them? Nutt D; Kilpatrick G; Hayes A Eur Neuropsychopharmacol; 2014 Apr; 24(4):487-90. PubMed ID: 24508534 [No Abstract] [Full Text] [Related]
12. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. Krumholz HM; Pasternak RC; Weinstein MC; Friesinger GC; Ridker PM; Tosteson AN; Goldman L N Engl J Med; 1992 Jul; 327(1):7-13. PubMed ID: 1598117 [TBL] [Abstract][Full Text] [Related]
13. Closing the gap. Nat Rev Drug Discov; 2006 Feb; 5(2):89. PubMed ID: 16521323 [No Abstract] [Full Text] [Related]
14. The cost-effectiveness of thrombolytic therapy following acute myocardial infarction. Fenn P; Gray AM; McGuire A Br J Clin Pract; 1991; 45(3):181-4. PubMed ID: 1805915 [TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology. Blue-chip technology. Flockhart DA; Webb DJ Lancet; 1998 Dec 19-26; 352 Suppl 4():SIV2. PubMed ID: 9872149 [No Abstract] [Full Text] [Related]
16. Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction. Kaul P; Armstrong PW; Cowper PA; Eisenstein EL; Granger CB; Van de Werf F; Mark DB Am Heart J; 2005 Apr; 149(4):637-44. PubMed ID: 15990746 [TBL] [Abstract][Full Text] [Related]
17. Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents. Woo KS; White HD Pharmacoeconomics; 1993 Mar; 3(3):192-204. PubMed ID: 10172049 [TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology in the People's Republic of China. Ogilvie RI Clin Invest Med; 1986 Nov; 9(4):340-1. PubMed ID: 3802623 [No Abstract] [Full Text] [Related]
20. Effect of age on myocardial infarction and thrombolysis. Morgan B; Emerman CL Am J Emerg Med; 1995 Mar; 13(2):196-8. PubMed ID: 7893308 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]